KR100991644B1 - 활성이 개량된 조합 모티프 면역자극성 올리고뉴클레오티드 - Google Patents
활성이 개량된 조합 모티프 면역자극성 올리고뉴클레오티드 Download PDFInfo
- Publication number
- KR100991644B1 KR100991644B1 KR1020047002289A KR20047002289A KR100991644B1 KR 100991644 B1 KR100991644 B1 KR 100991644B1 KR 1020047002289 A KR1020047002289 A KR 1020047002289A KR 20047002289 A KR20047002289 A KR 20047002289A KR 100991644 B1 KR100991644 B1 KR 100991644B1
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- immunostimulatory nucleic
- cancer
- odn
- ifn
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Abstract
Description
ODN | E:T 비율 | L.U. | |||||
3.1 | 6.3 | 12.5 | 25.0 | 50.0 | 100.0 | ||
단독 | 0.86 | 1.47 | 4.15 | 7.25 | 11.66 | 18.57 | 0.13 |
IL-2 (100 U/ml) | 12.21 | 29.21 | 46.63 | 67.88 | 78.28 | 76.65 | 33.26 |
1585 (3 ㎍/ml) | 6.47 | 12.61 | 24.65 | 36.82 | 49.30 | 53.00 | 11.69 |
1585 (10 ㎍g/ml) | 8.52 | 18.17 | 33.20 | 51.26 | 72.13 | 73.89 | 20.94 |
1585 (30 ㎍/ml) | 5.75 | 13.05 | 20.00 | 34.34 | 45.02 | 56.49 | 10.66 |
2118 (10 ㎍/ml) | 0.62 | 2.08 | 3.90 | 8.53 | 12.79 | 15.93 | 0.09 |
2006 (0.6 ㎍/ml) | 1.62 | 2.88 | 8.24 | 14.10 | 21.85 | 31.91 | 1.73 |
2006 (3 ㎍/ml) | 7.07 | 17.02 | 30.28 | 50.66 | 69.13 | 74.27 | 19.41 |
2169 (0.6 ㎍/ml) | 3.65 | 3.81 | 6.67 | 13.45 | 24.48 | 32.42 | 1.84 |
2169 (3 ㎍/ml) | 11.20 | 21.47 | 38.15 | 59.66 | 78.96 | 77.72 | 25.76 |
1760 (0.6 ㎍/ml) | 0.35 | 2.70 | 6.85 | 8.59 | 16.09 | 20.63 | 0.33 |
1760 (3 ㎍/ml) | 7.57 | 12.94 | 27.50 | 46.63 | 62.43 | 66.97 | 16.60 |
1758 (0.6 ㎍/ml) | 2.07 | 6.05 | 12.80 | 23.25 | 34.57 | 44.93 | 5.43 |
1758 (3 ㎍/ml) | 8.40 | 17.84 | 33.41 | 52.20 | 69.52 | 74.46 | 20.78 |
2398 (0.6 ㎍/ml) | 1.83 | 1.92 | 6.21 | 11.21 | 20.38 | 26.71 | 0.98 |
2398 (3 ㎍/ml) | 4.36 | 12.90 | 24.10 | 42.37 | 60.51 | 70.03 | 15.02 |
2397 (0.6 ㎍/ml) | 2.14 | 3.15 | 8.79 | 17.37 | 28.71 | 42.45 | 3.80 |
2397 (3 ㎍/ml) | 10.09 | 22.52 | 38.96 | 61.85 | 77.69 | 74.87 | 26.12 |
2396 (0.6 ㎍/ml) | 2.93 | 5.80 | 13.22 | 25.32 | 36.83 | 46.77 | 6.13 |
2396 (3 ㎍/ml) | 9.03 | 18.65 | 32.71 | 54.62 | 72.62 | 73.67 | 21.64 |
2395 (0.6 ㎍/ml) | 5.10 | 9.22 | 17.21 | 31.67 | 49.53 | 60.53 | 10.59 |
2395 (3 ㎍/ml) | 10.91 | 24.55 | 40.42 | 61.23 | 71.11 | 75.52 | 26.94 |
2136 (0.6 ㎍/ml) | 0.39 | 2.89 | 7.12 | 12.70 | 18.88 | 24.11 | 0.78 |
2136 (3 ㎍/ml) | 11.94 | 23.57 | 39.11 | 55.16 | 70.84 | 71.99 | 25.62 |
ODN | E:T 비율 | L.U. | |||||
3.1 | 6.3 | 12.5 | 25.0 | 50.0 | 100.0 | ||
단독 | 1.73 | 3.10 | 4.25 | 7.72 | 12.07 | 14.56 | 0.03 |
IL-2 (100 U/ml) | 16.68 | 29.41 | 49.42 | 74.78 | 87.64 | 92.63 | 37.17 |
1585 (10 ㎍/ml) | 9.60 | 17.25 | 35.63 | 55.76 | 77.53 | 87.14 | 22.94 |
2118 (10 ㎍/ml) | 2.99 | 2.88 | 3.41 | 6.72 | 9.26 | 14.18 | 0.01 |
2183 (0.6 ㎍/ml) | 2.13 | 2.28 | 3.29 | 8.17 | 10.47 | 17.87 | 0.07 |
2186 (0.6 ㎍/ml) | 1.23 | 2.18 | 3.50 | 6.26 | 9.58 | 14.51 | 0.02 |
2133 (0.6 ㎍/ml) | 2.13 | 3.45 | 9.69 | 18.85 | 32.72 | 44.67 | 4.63 |
2135 (0.6 ㎍/ml) | 2.07 | 4.06 | 7.70 | 12.63 | 21.90 | 34.58 | 1.92 |
2139 (0.6 ㎍/ml) | 2.94 | 5.15 | 9.63 | 15.15 | 24.90 | 38.71 | 2.83 |
2117 (0.6 ㎍/ml) | 1.21 | 2.32 | 4.08 | 7.61 | 10.09 | 16.27 | 0.05 |
2137 (0.6 ㎍/ml) | 1.66 | 2.79 | 4.43 | 7.92 | 10.64 | 16.91 | 0.06 |
2006 (0.6 ㎍/ml) | 1.92 | 3.38 | 5.06 | 11.57 | 16.82 | 25.30 | 0.65 |
2006 (0.6 ㎍/ml) | 0.91 | 2.19 | 4.52 | 7.39 | 13.86 | 21.57 | 0.28 |
2006 (0.6 ㎍/ml) | 1.92 | 3.59 | 7.67 | 12.51 | 18.99 | 28.03 | 1.04 |
2395 (0.6 ㎍/ml) | 2.88 | 7.20 | 10.80 | 23.96 | 37.97 | 54.38 | 7.02 |
2396 (0.6 ㎍/ml) | 0.92 | 2.18 | 4.07 | 5.78 | 10.18 | 14.95 | 0.03 |
2397 (0.6 ㎍/ml) | 3.05 | 5.24 | 10.51 | 17.50 | 33.51 | 46.50 | 4.92 |
2398 (0.6 ㎍/ml) | 1.37 | 2.82 | 5.16 | 8.48 | 15.72 | 21.72 | 0.3 |
2012 (0.6 ㎍/ml) | 0.88 | 1.71 | 4.41 | 7.07 | 10.97 | 16.47 | 0.06 |
2102 (0.6 ㎍/ml) | 2.36 | 5.82 | 10.59 | 17.88 | 30.96 | 39.79 | 3.81 |
2103 (0.6 ㎍/ml) | 2.12 | 4.32 | 8.83 | 13.49 | 25.23 | 35.47 | 2.37 |
2013 (0.6 ㎍/ml) | 1.11 | 2.42 | 4.42 | 6.01 | 9.15 | 13.44 | 0.01 |
2142 (0.6 ㎍/ml) | 0.94 | 1.55 | 4.38 | 7.44 | 11.45 | 16.84 | 0.08 |
2180 (0.6 ㎍/ml) | 2.06 | 4.08 | 6.91 | 11.54 | 16.82 | 25.76 | 0.67 |
2007 (0.6 ㎍/ml) | 1.83 | 3.30 | 6.68 | 12.34 | 20.74 | 29.10 | 1.25 |
2136 (0.6 ㎍/ml) | 0.01 |
ODN | E:T 비율 | L.U. | |||||
3.1 | 6.3 | 12.5 | 25.0 | 50.0 | 100.0 | ||
단독 | 0.37 | 0.64 | 0.25 | 1.02 | 2.15 | 3.23 | 0.00 |
IL-2 (100 U/ml) | 3.01 | 4.20 | 9.01 | 18.92 | 27.37 | 38.17 | 3.22 |
1585 (10 ㎍/ml) | 1.35 | 2.30 | 4.38 | 8.07 | 13.96 | 22.31 | 0.31 |
2118 (10 ㎍/ml) | -0.31 | -0.21 | 0.22 | 1.57 | 1.24 | 2.41 | 0.00 |
2395 (1 ㎍/ml) | 1.01 | 2.61 | 5.73 | 11.39 | 18.92 | 28.16 | 1.04 |
2395 (3 ㎍/ml) | 1.59 | 2.55 | 5.96 | 12.09 | 20.46 | 33.87 | 1.71 |
2006 (1 ㎍/ml) | -0.08 | 0.73 | 1.45 | 3.03 | 7.11 | 12.49 | 0.01 |
2006 (3 ㎍/ml) | 0.16 | 0.76 | 2.98 | 4.98 | 9.79 | 20.58 | 0.15 |
2427 (1 ㎍/ml) | 0.85 | 1.80 | 4.03 | 6.37 | 12.53 | 24.12 | 0.34 |
2427 (3 ㎍/ml) | 0.96 | 2.24 | 4.40 | 8.00 | 15.01 | 21.85 | 0.33 |
2428 (1 ㎍/ml) | 1.19 | 1.97 | 3.64 | 7.72 | 16.27 | 24.74 | 0.53 |
2428 (3 ㎍/ml) | 1.42 | 2.36 | 5.67 | 11.06 | 19.11 | 28.17 | 1.03 |
2429 (1 ㎍/ml) | 1.47 | 3.84 | 7.83 | 14.17 | 25.47 | 38.99 | 2.85 |
2429 (3 ㎍/ml) | 0.57 | 2.38 | 4.21 | 8.98 | 16.88 | 26.36 | 0.72 |
2430 (1 ㎍/ml) | 1.49 | 3.55 | 6.25 | 12.76 | 20.51 | 31.67 | 1.51 |
2430 (3 ㎍/ml) | 1.23 | 1.52 | 3.89 | 8.78 | 15.28 | 25.56 | 0.57 |
2431 (1 ㎍/ml) | 0.96 | 2.90 | 3.58 | 8.29 | 15.23 | 25.29 | 0.53 |
2431 (3 ㎍/ml) | 1.82 | 3.25 | 5.53 | 9.67 | 21.04 | 32.78 | 1.51 |
2432 (1 ㎍/ml) | 1.67 | 2.97 | 4.87 | 8.54 | 19.26 | 27.10 | 0.84 |
2432 (3 ㎍/ml) | 1.03 | 2.39 | 5.22 | 9.41 | 18.48 | 25.74 | 0.76 |
2433 (1 ㎍/ml) | 0.74 | 1.84 | 2.30 | 6.97 | 12.43 | 18.94 | 0.15 |
2433 (3 ㎍/ml) | 1.25 | 3.13 | 4.47 | 9.85 | 14.77 | 22.75 | 0.38 |
ODN, 6 ㎍/ml | IFN-α, pg/ml | |
D141 | D142 | |
2006 | 10 ±10 | 7 ±0.5 |
2336 | 83,297 ±1876.5 | 53530.5 ±4840 |
2395 | 6214 ±84.5 | 2031 ±96 |
2429 | 7215 ±68 | 1117.5 ±495 |
5293 | 10 ±0.5 | 27 ±27 |
5294 | 2.5 ±0.1 | 23 ±23 |
5295 | 5 ±0.5 | 0 ±0 |
5296 | 10 ±0 | 10 ±0 |
5297 | 10 ±0.5 | 26.5 ±1 |
부재 (w/o) | 110 ±77.5 | 12 ±12 |
1 데이터는 pg/ml 단위로, 평균 ±표준 편차 형태로 나타냄 |
ODN | 서열 | 서열 | 팔린드롬 | 설명 | IFN-α유도 |
2006 | 39 | tcgtcgttttgtcgttttgtcgtt | / | ODN 클래스 B | - |
2336 | 57 | ggGGACGACGTCCTGgggggG | + | ODN 클래스 A | +++++ |
2395 | 1 | tcgtcgttttcggcgcgcgccg | + | 2006 - 2136 | ++ |
2427 | 2 | tcgtcgttttcgtcgcgcgccg | - | - | |
2428 | 3 | tcgtcgttttcgtcgcgcggcg | - | - | |
2429 | 4 | tcgtcgttttcggcg gc cgccg | + | 팔린드롬 보존에 의해 cg→gc | +++ |
2430 | 5 | tcgtcgttttcggcgcgccgcg | - | + | |
2431 | 6 | tcgtcgttttcggcgcgccgcg | - | +/- | |
2432 | 7 | tcgtcgttttcggcccgcgcgg | - | + | |
2433 | 8 | tcgtcgttttccgccgccgggg | - | - | |
5293 | 58 | tcgtcgttttcggcg gc cgcc | (+) | 2429 w/o 3'g | - |
5294 | 59 | tcgtcgttttcggccgccgcc | - | 3xgcc w/o 3'g | - |
5295 | 60 | tcgtcgttttcggccgccgccg | - | 5295 w/3'g | - |
5296 | 61 | tcgtcgttttcgccgccgccg | - | - | |
5297 | 62 | tgctgcttttcggcg gc cgccg | + | 2429의 gc | - |
5327 | 14 | tgctzgttttzggzgzgzgzzg | + | 2395 w/메틸-c (z) | + |
5328 | 15 | tgctgcttttcggcgcgcgccg | + | 2395의 gc | - |
2136 | 19 | tcctgacgttcggcgcgcgccc | (+) | +/- | |
5315 | 13 | tcctgacgttcggcgcgcgccg | + | 2136 w/3'g 더 긴 팔린드롬 |
+? |
5329 | 16 | tcgtcgttttcgcgcgcgcgcg | + | 2006 + 1631 | (-) |
1 2395와 다른 뉴클레오티드에는 밑줄, 팔린드롬 서열은 이탤릭체로 표시 2 키메라 골격 ODN (대문자는 포스포디에스테르 연결기를 나타내고 소문자는 포스포로티오에이트 연결기를 나타냄)을 대표하는 ODN 2336을 제외하고는 모두 완전히 포스포로티오에이트 ODN임 |
ODN | TNF-α, pg/ml |
(LPS) | >120 |
2006 | 40 |
2429 | 35 |
2395 | 21 |
8954 | 14 |
없음 | 16 |
ODN | 농도 ㎍/ml |
D346 평균 ± 표준편차 |
D240 평균 ± 표준편차 |
2006 |
0.8 | 18.5 ±13.8 | 36 ±3.3 |
2.4 | 0 ±0 | 19.7 ±6.4 | |
6 | 2.7 ±0 | 2.8 ±0 | |
5515 |
0.8 | 34.1 ±6.9 | 16.5 ±2.8 |
2.4 | 36.6 ±2.1 | 106.7 ±17.3 | |
6 | 39.2 ±26.5 | 127.3 ±7.7 | |
5516 |
0.8 | 4.3 ±0 | 22.3 ±0.1 |
2.4 | 31.9 ±0 | 172.5 ±82.3 | |
6 | 26.6 ±19 | 90.4 ±15.4 | |
없음 | -- | 0 ±0 | 20.9 ±6.5 |
ODN | 농도 ㎍/ml |
D445 평균 ± 표준편차 |
D446 평균 ± 표준편차 |
D448 평균 ± 표준편차 |
2006 |
0.05 | 5.2 ±0.0 | 58.8 ±1.9 | 0.9 ±0.0 |
0.1 | 27.7 ±14.4 | 283.5 ±16.1 | 23.5 ±3.8 | |
0.2 | 54.9 ±17.6 | 503.7 ±9.7 | 39.1 ±5.0 | |
0.5 | 61.1 ±14.6 | 227.8 ±12.7 | 49.8 ±0.4 | |
1.0 | 26.4 ±15.5 | 142.6 ±23.1 | 48.7 ±29.8 | |
20184 |
0.05 | 25.6 ±2.1 | 88.0 ±12.2 | 0.0 ±0.0 |
0.1 | 32.9 ±7.3 | 691.2 ±32.3 | 129.1 ±24.8 | |
0.2 | 256.2 ±8.2 | 2155.1 ±35.1 | 314.0 ±22.2 | |
0.5 | 757.2 ±5.7 | 2171.8 ±95.9 | 268.7 ±15.9 | |
1.0 | 194.3 ±5.7 | 1181.9 ±15.1 | 5.8 ±3.4 | |
20185 |
0.05 | 65.0 ±10.8 | 217.9 ±28.4 | 54.3 ±14.2 |
0.1 | 63.6 ±1.3 | 467.4 ±23.7 | 150.9 ±5.9 | |
0.2 | 79.3 ±2.4 | 1420.5 ±83.7 | 160.2 ±5.5 | |
0.5 | 281.3 ±0.2 | 1965.7 ±72.3 | 162.4 ±3.8 | |
1.0 | 176.9 ±12.5 | 1710.3 ±19.7 | 181.1 ±0.1 | |
20186 |
0.05 | 21.9 ±1.7 | 223.1 ±1.2 | 79.8 ±1.6 |
0.1 | 58.3 ±7.6 | 812.2 ±28.1 | 111.3 ±6.8 | |
0.2 | 153.6 ±1.5 | 1302.5 ±56.2 | 193.5 ±10.5 | |
0.5 | 267.7 ±7.9 | 1744.1 ±54.7 | 227.4 ±6.9 | |
1.0 | 153.0 ±0.3 | 1113.6 ±6.4 | 13.7 ±15.4 | |
매질 | -- | 0.0 ±0.0 | 12.8 ±2.0 | 64.8 ±32.7 |
-- | 0.0 ±0.0 | 45.3 ±12.9 | 36.4 ±2.6 |
ODN | 농도 ㎍/ml |
D521 평균 ± 표준편차 |
D525 평균 ± 표준편차 |
D526 평균 ± 표준편차 |
2006 |
0.03 | 238.674 | 239.286 | 216.393 |
0.06 | 2405.63 | 385.161 | 126.516 | |
0.125 | 3826.53 | 549.612 | 86.173 | |
0.25 | 2248.94 | 532.67 | 74.493 | |
1.0 | 362.74 | 161.892 | 57.087 | |
8954 |
0.03 | 305.626 | 309.581 | 599.971 |
0.06 | 6039.51 | 2028.52 | 4707.01 | |
0.125 | 7322.45 | 4669.31 | 5340.21 | |
0.25 | 7651.13 | 4641.1 | 5324.55 | |
1.0 | 7078.59 | 4679.59 | 5474.94 | |
5569 |
0.03 | 112.784 | 121.422 | 87.751 |
0.06 | 110.723 | 65.753 | 47.888 | |
0.125 | 104.547 | 49.365 | 41.046 | |
0.25 | 111.755 | 62.383 | 43.216 | |
1.0 | 2247.97 | 115.77 | 1101.58 | |
5570 |
0.03 | 822.648 | 427.535 | 250.196 |
0.06 | 1858.16 | 1021.18 | 218.201 | |
0.125 | 3470.67 | 1657.3 | 477.938 | |
0.25 | 5612.53 | 3369.99 | 669.706 | |
1.0 | 6798.3 | 3501.59 | 2560.93 | |
매질 |
-- | 145.436 | 214.212 | 66.853 |
-- | 245.121 | 218.622 | 0 |
ODN | 농도 ㎍/ml |
D521 평균 ± 표준편차 |
D525 평균 ± 표준편차 |
D526 평균 ± 표준편차 |
2006 | 0.03 | 151.976 | 112.414 | 485.823 |
0.06 | 384.377 | 218.651 | 898.299 | |
0.125 | 404.352 | 242.289 | 991.614 | |
0.25 | 357.657 | 247.405 | 1150.94 | |
1.0 | 255.344 | 162.444 | 1171.72 | |
8954 | 0.03 | 7.456 | 6.617 | 6.919 |
0.06 | 5.34 | 5.721 | 19.787 | |
0.125 | 10.723 | 2.986 | 35.892 | |
0.25 | 15.308 | 13.056 | 67.18 | |
1.0 | 48.904 | 30.892 | 230.725 | |
5569 | 0.03 | 0 | 1.287 | 1.348 |
0.06 | 0 | 0.127 | 4.592 | |
0.125 | 18.815 | 3.615 | 62.963 | |
0.25 | 105.32 | 30.094 | 350.529 | |
1.0 | 256.785 | 136.833 | 1156.07 | |
5570 | 0.03 | 0 | 0.31 | 5.867 |
0.06 | 6.599 | 7.027 | 29.879 | |
0.125 | 98.553 | 38.528 | 455.145 | |
0.25 | 259.812 | 107.164 | 1169.46 | |
1.0 | 312.189 | 206.126 | 1595.63 | |
매질 | -- | 1.755 | 10.543 | 0 |
-- | 0.29 | 11.192 | 0 |
Claims (72)
- 하기 식:5' PX1DCGHX2 3' 또는 5' X1DCGHX2P 3'을 포함하는 염기 서열을 갖고,식 중, X1 및 X2는 독립적으로 0 내지 10개 염기 길이의 임의의 서열이고, D는 C 이외의 염기이며, C는 시토신이고, G는 구아닌이며, H는 G 이외의 염기이고, P는 길이가 10개 염기 이상인 GC-풍부 팔린드롬 포함 서열이며, 여기서a) H는 티민(T)이며, X2는 CGTTT 또는 CGTTTT이고,b) P는 완전히 팔린드롬이고, H는 T이며, X2는 CG, CGT, CGTT, CGTTT 및 CGTTTT로 이루어진 군으로부터 선택되고(되거나),c) P는 하나 이상의 하이포잔틴(hypoxanthine)(I)을 포함하는 것인,14 내지 100개 뉴클레오티드 길이의 면역자극성 핵산.
- 제1항에 있어서, 염기 서열이a) 5' X1DCGHX2PX3 3'(여기서, X3은 0 내지 10개 염기 길이의 임의의 서열임),b) 5' X1DCGHPX3 3'(여기서, X3은 0 내지 10개 염기 길이의 임의의 서열임),c) 5' DCGHX2PX3 3'(여기서, X3은 0 내지 10개 염기 길이의 임의의 서열임),d) 5' TCGHX2PX3 3'(여기서, X3은 0 내지 10개 염기 길이의 임의의 서열임),e) 5' DCGHPX3 3'(여기서, X3은 0 내지 10개 염기 길이의 임의의 서열임), 및(또는)f) 5' DCGHP 3'를 포함하는 것인 면역자극성 핵산.
- 하기 식:5' NX1DCGHX2 3' 또는 5' X1DCGHX2N 3'을 포함하는 염기 서열을 갖고,식 중, X1 및 X2는 독립적으로 0 내지 10개 염기 길이의 임의의 서열이고, D는 C 이외의 염기이며, C는 시토신이고, G는 구아닌이며, H는 G 이외의 염기이고, N은 CGG로 시작하고 길이가 10개 염기 이상인 B-세포 중화 서열이며, 여기서1) 5' NX1DCGHX2 3'에 대하여:a) H는 티민(T)이고(이거나),b) H는 T이며, X2는 CG, CGT, CGTT, CGTTT 및 CGTTTT로 이루어진 군으로부터 선택되고,2) 5' X1DCGHX2N 3'에 대하여:a) H는 T이며, X2는 CGTTTT인,14 내지 100개 뉴클레오티드 길이의 면역자극성 핵산.
- 제1항에 있어서, 식 5' PX1DCGHX2 3' 및 5' X1DCGHX2P 3'에서 C가 메틸화되지 않은 것인 면역자극성 핵산.
- 제3항에 있어서, 식 5' NX1DCGHX2 3' 및 5' X1DCGHX2N 3'에서 C가 메틸화되지 않은 것인 면역자극성 핵산.
- 제1항 내지 제5항 중 어느 한 항에 있어서,a) 뉴클레아제-저항성 골격을 갖고(갖거나),b) 포스포로티오에이트 골격을 갖고(갖거나),c) 키메라 골격을 갖고(갖거나),d) 길이가 14-40개 뉴클레오티드이고(이거나),e) 길이가 14-30개 뉴클레오티드인,면역자극성 핵산.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 염기 서열이 5' 말단 및(또는) 3' 말단에 폴리-T 서열을 추가로 포함하는 면역자극성 핵산.
- 제6항에 있어서, 염기 서열이 5' 말단 및(또는) 3' 말단에 폴리-T 서열을 추가로 포함하는 면역자극성 핵산.
- 하기 식:5' N1PyGN2P 3'을 포함하는 염기 서열을 갖고,식 중, N1은 1 내지 6개 염기 길이의 임의의 서열이고, Py는 피리미딘이며, G는 구아닌이고, N2는 0 내지 30개 염기 길이의 임의의 서열이며, P는 길이가 10개 염기 이상인 GC-풍부 팔린드롬 포함 서열이고, 여기서 N1은a) 하나 이상의 시토신-하이포잔틴(CI) 모티프를 포함하고(하거나),b) 하나 이상의 TCI 모티프를 포함하고(하거나),c) 하나 이상의 IG 모티프를 포함하고(하거나),d) 하나 이상의 TIG 모티프를 포함하고(하거나),e) TCGG인,13 내지 100개 뉴클레오티드 길이의 면역자극성 핵산.
- 제9항에 있어서,a) Py가 메틸화되지 않은 C이고(이거나),b) N2의 50% 이상이 피리미딘이고(이거나),c) N2의 50% 이상이 T이고(이거나),d) N2가 폴리-G 또는 폴리-A 모티프를 포함하지 않고(않거나),e) N1PyGN2가 TTTCG, TTTTCG, TTTTTCG, TTCGT 및 TTTCGT로 이루어진 군으로부터 선택되는 서열인,면역자극성 핵산.
- 제9항에 있어서,a) 완전히 뉴클레아제-저항성 골격(임의로, 뉴클레아제-저항성 골격은 포스포로티오에이트 연결부로 이루어짐)을 갖고(갖거나),b) 완전히 포스포디에스테르 골격을 갖고(갖거나),c) 키메라 골격을 갖는,면역자극성 핵산.
- 제9항에 있어서, P가a) 완전히 팔린드롬이고(이거나),b) 1 내지 3개의 연속되는 개재 염기를 갖는 팔린드롬 서열이고(이거나),c) 3개 이상의 C 및 3개 이상의 G 염기를 포함하고(하거나),d) 4개 이상의 C 및 4개 이상의 G 염기를 포함하고(하거나),e) 5개 이상의 C 및 5개 이상의 G 염기를 포함하고(하거나),f) 하나 이상의 하이포잔틴을 포함하는 것인,면역자극성 핵산.
- 제9항에 있어서,a) 13 내지 40개 뉴클레오티드 길이이고(이거나),b) 13 내지 30개 뉴클레오티드 길이인,면역자극성 핵산.
- 하기 식:5' N1PyG/IN2P 3'을 포함하는 염기 서열을 갖고,식 중, N1은 1 내지 6개 염기 길이의 임의의 서열이고, Py는 피리미딘이며, G/I는 G 또는 I인 단일 염기를 나타내고, G는 구아닌이며, I는 하이포잔틴이고, N2는 0 내지 30개 염기 길이의 임의의 서열이며, P는 길이가 10개 염기 이상인 팔린드롬 포함 서열이고, 여기서 G/I가 G일 때, P는 IC-풍부 팔린드롬인,13 내지 100개 뉴클레오티드 길이의 면역자극성 핵산.
- 제14항에 있어서, G/I가 I일 때a) N1PyIN2가 TCITCITTTT(서열 47)이고(이거나),b) P가 GC-풍부 팔린드롬이고(이거나),c) P가 IC-풍부 팔린드롬인,면역자극성 핵산.
- 제14항에 있어서, 13 내지 30개 뉴클레오티드 길이인 면역자극성 핵산.
- 제1항 내지 제5항 및 제9항 내지 제16항 중 어느 한 항에 따른 면역자극성 핵산과 제약상 허용되는 담체를 포함하는 제약 조성물.
- 제6항에 따른 면역자극성 핵산과 제약상 허용되는 담체를 포함하는 제약 조성물.
- 제7항에 따른 면역자극성 핵산과 제약상 허용되는 담체를 포함하는 제약 조성물.
- 제8항에 따른 면역자극성 핵산과 제약상 허용되는 담체를 포함하는 제약 조성물.
- 제17항에 있어서, 항원, 임의로 종양 항원을 추가로 포함하는 제약 조성물
- 제1형 인터페론(IFN)을 발현할 수 있는 세포를 제1항 내지 제5항 및 제9항 내지 제16항 중 어느 한 항에 따른 면역자극성 핵산과 접촉시키는 것을 포함하는, 제1형 IFN의 발현을 유도하기 위한 시험관내 방법.
- 제1형 인터페론(IFN)을 발현할 수 있는 세포를 제6항에 따른 면역자극성 핵산과 접촉시키는 것을 포함하는, 제1형 IFN의 발현을 유도하기 위한 시험관내 방법.
- 제1형 인터페론(IFN)을 발현할 수 있는 세포를 제7항에 따른 면역자극성 핵산과 접촉시키는 것을 포함하는, 제1형 IFN의 발현을 유도하기 위한 시험관내 방법.
- 제1형 인터페론(IFN)을 발현할 수 있는 세포를 제8항에 따른 면역자극성 핵산과 접촉시키는 것을 포함하는, 제1형 IFN의 발현을 유도하기 위한 시험관내 방법.
- 자연 살해(NK) 세포를 제1항 내지 제5항 및 제9항 내지 제16항 중 어느 한 항에 따른 면역자극성 핵산과 접촉시키는 것을 포함하는, NK 세포를 활성화하기 위한 시험관내 방법.
- 자연 살해(NK) 세포를 제6항에 따른 면역자극성 핵산과 접촉시키는 것을 포함하는, NK 세포를 활성화하기 위한 시험관내 방법.
- 자연 살해(NK) 세포를 제7항에 따른 면역자극성 핵산과 접촉시키는 것을 포함하는, NK 세포를 활성화하기 위한 시험관내 방법.
- 자연 살해(NK) 세포를 제8항에 따른 면역자극성 핵산과 접촉시키는 것을 포함하는, NK 세포를 활성화하기 위한 시험관내 방법.
- 제1항 내지 제5항 및 제9항 내지 제16항 중 어느 한 항에 있어서, 제1형 인터페론(IFN)을 발현할 수 있는 세포와 접촉시켜 제1형 IFN의 발현을 유도하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제6항에 있어서, 제1형 인터페론(IFN)을 발현할 수 있는 세포와 접촉시켜 제1형 IFN의 발현을 유도하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제7항에 있어서, 제1형 인터페론(IFN)을 발현할 수 있는 세포와 접촉시켜 제1형 IFN의 발현을 유도하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제8항에 있어서, 제1형 인터페론(IFN)을 발현할 수 있는 세포와 접촉시켜 제1형 IFN의 발현을 유도하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제1항 내지 제5항 및 제9항 내지 제16항 중 어느 한 항에 있어서, 자연 살해(NK) 세포와 접촉시켜 NK 세포를 활성화하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제6항에 있어서, 자연 살해(NK) 세포와 접촉시켜 NK 세포를 활성화하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제7항에 있어서, 자연 살해(NK) 세포와 접촉시켜 NK 세포를 활성화하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제8항에 있어서, 자연 살해(NK) 세포와 접촉시켜 NK 세포를 활성화하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제1항 내지 제5항 및 제9항 내지 제16항 중 어느 한 항에 있어서, 감염증에 걸려 있거나 발병할 위험이 있는 대상에서 감염증을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제6항에 있어서, 감염증에 걸려 있거나 발병할 위험이 있는 대상에서 감염증을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제7항에 있어서, 감염증에 걸려 있거나 발병할 위험이 있는 대상에서 감염증을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제8항에 있어서, 감염증에 걸려 있거나 발병할 위험이 있는 대상에서 감염증을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제38항에 있어서, 대상이 바이러스, 세균, 진균 및 기생충 감염으로 이루어진 군으로부터 선택된 감염증에 걸려 있거나 발병할 위험이 있는 것인, 면역자극성 핵산.
- 제39항에 있어서, 대상이 바이러스, 세균, 진균 및 기생충 감염으로 이루어진 군으로부터 선택된 감염증에 걸려 있거나 발병할 위험이 있는 것인, 면역자극성 핵산.
- 제40항에 있어서, 대상이 바이러스, 세균, 진균 및 기생충 감염으로 이루어진 군으로부터 선택된 감염증에 걸려 있거나 발병할 위험이 있는 것인, 면역자극성 핵산.
- 제41항에 있어서, 대상이 바이러스, 세균, 진균 및 기생충 감염으로 이루어진 군으로부터 선택된 감염증에 걸려 있거나 발병할 위험이 있는 것인, 면역자극성 핵산.
- 제1항 내지 제5항 및 제9항 내지 제16항 중 어느 한 항에 있어서, 알레르기성 질환에 걸려 있거나 발병할 위험이 있는 대상에서 알레르기성 질환을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제6항에 있어서, 알레르기성 질환에 걸려 있거나 발병할 위험이 있는 대상에서 알레르기성 질환을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제7항에 있어서, 알레르기성 질환에 걸려 있거나 발병할 위험이 있는 대상에서 알레르기성 질환을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제8항에 있어서, 알레르기성 질환에 걸려 있거나 발병할 위험이 있는 대상에서 알레르기성 질환을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제46항에 있어서, 알레르기성 질환이 알레르기성 천식인 면역자극성 핵산.
- 제47항에 있어서, 알레르기성 질환이 알레르기성 천식인 면역자극성 핵산.
- 제48항에 있어서, 알레르기성 질환이 알레르기성 천식인 면역자극성 핵산.
- 제49항에 있어서, 알레르기성 질환이 알레르기성 천식인 면역자극성 핵산.
- 제1항 내지 제5항 및 제9항 내지 제16항 중 어느 한 항에 있어서, 암에 걸려 있거나 발병할 위험이 있는 대상에서 암을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제6항에 있어서, 암에 걸려 있거나 발병할 위험이 있는 대상에서 암을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제7항에 있어서, 암에 걸려 있거나 발병할 위험이 있는 대상에서 암을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제8항에 있어서, 암에 걸려 있거나 발병할 위험이 있는 대상에서 암을 치료 또는 예방하는 것을 포함하는 치료 방법에 사용하기 위한 면역자극성 핵산.
- 제54항에 있어서, 암이 기저세포암, 담도암, 방광암, 골암, 뇌 및 중추신경계암, 유방암, 자궁경부암, 융모상피암, 결장 및 직장암, 결합조직 암, 소화기계암, 자궁내막암, 식도암, 안암, 두부 및 경부암, 위암, 상피내 신생물, 신장암, 후두암, 백혈병, 간암, 폐암, 호지킨형 및 비호지킨형 림프종을 포함한 림프종, 흑색종, 골수종, 신경아종, 구강암, 난소암, 췌장암, 전립선암, 망막모세포종, 횡문근육종, 직장암, 신장암, 호흡기계암, 육종, 피부암, 위암, 고환암, 갑상선암, 자궁암, 비뇨기계암, 및 기타 암종 및 육종으로 이루어진 군으로부터 선택되는 것인 면역자극성 핵산.
- TCGTCGTTTTCGGCGCGCGCCG (서열 1),TCGTCGTTTTCGGCGGCCGCCG (서열 4),TCGTCGTTTTCGGCGCGCCGCG (서열 5),TCGTCGTTTTCGGCGCCGGCCG (서열 6),TCGTCGTTTTCGGCCCGCGCGG (서열 7),TCGTCGTTTTCGGCGCGCGCCGTTTTT (서열 12),TCCTGACGTTCGGCGCGCGCCG (서열 13),TZGTZGTTTTZGGZGZGZGZZG (서열 14)(여기서, Z는 5-메틸시토신임), 또는TCGGCGCGCGCCGTCGTCGTTT (서열 11)을 포함하는 염기 서열을 갖는 면역자극성 핵산.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31327301P | 2001-08-17 | 2001-08-17 | |
US60/313,273 | 2001-08-17 | ||
US39395202P | 2002-07-03 | 2002-07-03 | |
US60/393,952 | 2002-07-03 | ||
PCT/US2002/026468 WO2003015711A2 (en) | 2001-08-17 | 2002-08-19 | Combination motif immune stimulatory oligonucleotides with improved activity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040036714A KR20040036714A (ko) | 2004-04-30 |
KR100991644B1 true KR100991644B1 (ko) | 2010-11-02 |
Family
ID=26978772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047002289A KR100991644B1 (ko) | 2001-08-17 | 2002-08-19 | 활성이 개량된 조합 모티프 면역자극성 올리고뉴클레오티드 |
Country Status (23)
Country | Link |
---|---|
US (1) | US8834900B2 (ko) |
EP (1) | EP1446162B1 (ko) |
JP (2) | JP4383534B2 (ko) |
KR (1) | KR100991644B1 (ko) |
CN (1) | CN1604795B (ko) |
AT (1) | ATE411054T1 (ko) |
AU (1) | AU2002331643B2 (ko) |
BR (1) | BR0211962A (ko) |
CA (1) | CA2457485C (ko) |
CY (1) | CY1109398T1 (ko) |
DE (1) | DE60229422D1 (ko) |
DK (1) | DK1446162T3 (ko) |
EA (1) | EA007232B1 (ko) |
ES (1) | ES2314099T3 (ko) |
HK (1) | HK1067547A1 (ko) |
IL (2) | IL160157A0 (ko) |
MX (1) | MXPA04001458A (ko) |
NZ (2) | NZ531194A (ko) |
PT (1) | PT1446162E (ko) |
SG (1) | SG177000A1 (ko) |
SI (1) | SI1446162T1 (ko) |
WO (1) | WO2003015711A2 (ko) |
ZA (1) | ZA200401531B (ko) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
EP1067956B1 (en) * | 1998-04-03 | 2007-03-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
DE69932717T2 (de) * | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | Methoden und produkte zur induzierung mukosaler immunität |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
EP2204186B1 (en) | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
JP2003510282A (ja) * | 1999-09-25 | 2003-03-18 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫刺激核酸 |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
WO2001095935A1 (en) * | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
CA2410371C (en) * | 2000-06-22 | 2015-11-17 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
WO2002022809A2 (en) * | 2000-09-15 | 2002-03-21 | Coley Pharmaceutical Gmbh | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
ATE398175T1 (de) * | 2000-12-08 | 2008-07-15 | Coley Pharmaceuticals Gmbh | Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung |
CA2430691A1 (en) | 2000-12-27 | 2002-07-04 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
PT1404873E (pt) * | 2001-06-21 | 2013-07-30 | Dynavax Tech Corp | Compostos de imunomodulação quiméricos e métodos de utilização dos mesmos |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
AU2002361468A1 (en) | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
WO2003015711A2 (en) | 2001-08-17 | 2003-02-27 | Coley Pharmaceutical Group, Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
CA2461315A1 (en) * | 2001-10-05 | 2003-04-17 | Coley Pharmaceutical Gmbh | Toll-like receptor 3 signaling agonists and antagonists |
JP2005519990A (ja) * | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物 |
US7615227B2 (en) | 2001-12-20 | 2009-11-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce angiogenesis |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
ES2543710T3 (es) | 2002-04-04 | 2015-08-21 | Zoetis Belgium S.A. | Oligorribonucleótidos inmunoestimulantes que contienen G y U |
WO2003103586A2 (en) * | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AU2003247880B2 (en) * | 2002-07-03 | 2010-09-02 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
WO2004007743A2 (en) * | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
CN1753687A (zh) * | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
DE60329223D1 (de) * | 2002-12-23 | 2009-10-22 | Dynavax Tech Corp | Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung |
KR20060016817A (ko) * | 2003-06-20 | 2006-02-22 | 콜리 파마슈티칼 게엠베하 | 소분자 톨-유사 수용체 (tlr) 길항제 |
WO2005030259A2 (en) | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
US8188254B2 (en) * | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
KR100558851B1 (ko) * | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 CpG 올리고데옥시뉴클레오티드변형체 |
EP1781325A2 (en) * | 2004-07-18 | 2007-05-09 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
US20060241076A1 (en) * | 2005-04-26 | 2006-10-26 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
EP1957647B1 (en) | 2005-11-25 | 2015-03-04 | Zoetis Belgium S.A. | Immunostimulatory oligoribonucleotides |
DK1991678T4 (da) | 2006-02-15 | 2020-10-19 | Rechtsanwalt Thomas Beck | Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer |
WO2007139190A1 (ja) | 2006-05-31 | 2007-12-06 | Toray Industries, Inc. | 免疫刺激オリゴヌクレオチド及びその医薬用途 |
US20080026986A1 (en) * | 2006-06-05 | 2008-01-31 | Rong-Fu Wang | Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
MX2009003398A (es) * | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
EP2104738A2 (en) * | 2006-10-26 | 2009-09-30 | Coley Pharmaceuticals GmbH | Oligoribonucleotides and uses thereof |
WO2008057529A2 (en) * | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
EP2160199A2 (en) | 2007-05-17 | 2010-03-10 | Coley Pharmaceutical Group, Inc. | Class a oligonucleotides with immunostimulatory potency |
PT2170353E (pt) * | 2007-05-18 | 2015-09-16 | Adiutide Pharmaceuticals Gmbh | Análogos de oligonucleotídeo modificados por fosfato com atividade imunoestimulante |
CA2696460A1 (en) | 2007-08-13 | 2009-02-19 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
JP4847609B2 (ja) | 2007-08-13 | 2011-12-28 | コーリー ファーマシューティカル ゲーエムベーハー | 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるrna配列モチーフ |
CN101820908A (zh) * | 2007-10-09 | 2010-09-01 | 科利制药公司 | 包含改性糖部分的免疫刺激寡核苷酸类似物 |
WO2009156960A2 (en) | 2008-06-27 | 2009-12-30 | Pfizer Inc. | Novel adjuvant compositions |
NZ601345A (en) | 2008-10-16 | 2014-05-30 | Univ Dalhousie | Combination adjuvant formulation |
PL2411521T3 (pl) | 2009-03-25 | 2015-08-31 | Univ Texas | Kompozycje do stymulacji wrodzonej odporności immunologicznej na patogeny u ssaków |
KR101450958B1 (ko) | 2009-04-30 | 2014-10-15 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 폐렴구균 백신 및 그의 용도 |
JP2011251963A (ja) | 2010-05-28 | 2011-12-15 | Coley Pharmaceutical Group Inc | 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用 |
EP3441404A1 (en) | 2010-09-09 | 2019-02-13 | Pfizer Inc | 4-1bb binding molecules |
EP2640426B1 (en) * | 2010-11-16 | 2016-02-03 | Selecta Biosciences, Inc. | Immunostimulatory oligonucleotides |
EP2471926A3 (en) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
CN103547674A (zh) * | 2011-05-26 | 2014-01-29 | 英特维特国际股份有限公司 | 免疫刺激性寡脱氧核苷酸 |
CN103717070A (zh) | 2011-06-01 | 2014-04-09 | 贾纳斯生物治疗有限公司 | 新型免疫系统调节剂 |
AU2012262021B2 (en) | 2011-06-01 | 2016-07-28 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
WO2013052550A2 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
NZ625592A (en) | 2012-01-16 | 2016-09-30 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
JP2014012650A (ja) * | 2012-07-05 | 2014-01-23 | Nihon Univ | 上皮バリア機能の増強方法及び増強剤 |
MX356830B (es) | 2012-07-13 | 2018-06-15 | Shin Nippon Biomedical Laboratories Ltd | Adyuvante de acido nucleico quiral. |
EP2898073A4 (en) | 2012-09-21 | 2016-03-23 | Elizabeth Mckenna | Naturally-occurring CPG-oligonucleotide compositions and therapeutic applications thereof |
CN109675025A (zh) | 2013-09-19 | 2019-04-26 | 硕腾服务有限责任公司 | 油基佐剂 |
US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
WO2016029077A1 (en) | 2014-08-22 | 2016-02-25 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
EP3835312A1 (en) | 2014-12-31 | 2021-06-16 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
IL253137B2 (en) | 2015-01-16 | 2024-03-01 | Zoetis Services Llc | Vaccination for foot and mouth disease |
EP3436066A1 (en) | 2016-04-01 | 2019-02-06 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
WO2017201390A1 (en) | 2016-05-19 | 2017-11-23 | The Regents Of The University Of Michigan | Novel adjuvant compositions |
WO2018141810A1 (en) * | 2017-01-31 | 2018-08-09 | Alf Lamprecht | Use of nanoparticles for immunotherapy |
CN111511762A (zh) | 2017-08-21 | 2020-08-07 | 天演药业公司 | 抗cd137分子及其用途 |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
SG11202010934SA (en) | 2018-05-23 | 2020-12-30 | Pfizer | Antibodies specific for gucy2c and uses thereof |
KR102602329B1 (ko) | 2018-05-23 | 2023-11-16 | 화이자 인코포레이티드 | Cd3에 특이적인 항체 및 이의 용도 |
WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
JP2022522351A (ja) | 2019-02-28 | 2022-04-18 | スクイーズ バイオテクノロジーズ カンパニー | 免疫応答を改変するためのpbmcへの生体分子の送達 |
US11702474B2 (en) | 2019-12-17 | 2023-07-18 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
WO2023034278A1 (en) * | 2021-08-31 | 2023-03-09 | President And Fellows Of Harvard College | Interferon- inducing complexes and rna duplexes and methods of use |
WO2023081813A1 (en) | 2021-11-05 | 2023-05-11 | St. Jude Children's Research Hospital, Inc. | Zip cytokine receptors |
WO2023240182A1 (en) | 2022-06-08 | 2023-12-14 | St. Jude Children's Research Hospital, Inc. | Disruption of kdm4a in t cells to enhance immunotherapy |
WO2024059787A1 (en) | 2022-09-16 | 2024-03-21 | St. Jude Children's Research Hospital, Inc. | Disruption of asxl1 in t cells to enhance immunotherapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001022972A2 (en) * | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
WO2001055370A2 (en) * | 2000-01-26 | 2001-08-02 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
Family Cites Families (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US384480A (en) * | 1888-06-12 | Signor to the faebweeke | ||
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
WO1983001451A1 (en) | 1981-10-23 | 1983-04-28 | Molecular Biosystems Inc | Oligonucleotide therapeutic agent and methods of making same |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
CA1339596C (en) | 1987-08-07 | 1997-12-23 | New England Medical Center Hospitals, Inc. | Viral expression inhibitors |
US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5457189A (en) | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5514788A (en) | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5514577A (en) | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
US5248670A (en) | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
CA2084987C (en) | 1990-06-11 | 2007-02-13 | Larry Gold | Nucleic acid ligands |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
JPH04352724A (ja) * | 1990-07-27 | 1992-12-07 | Mitsui Toatsu Chem Inc | 免疫調節型治療剤 |
BR9106751A (pt) | 1990-08-16 | 1993-08-17 | Isis Pharmaceuticals Ind | Oligonucleotideo ou analogo de nucleotideo e processo para modulacao da atividade de uma infeccao por citomegalovirus |
WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US5582986A (en) | 1991-06-14 | 1996-12-10 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US6498147B2 (en) | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
ATE171210T1 (de) | 1992-07-02 | 1998-10-15 | Hybridon Inc | Selbststabilisierte oligonukleotide als therapeutika |
DE69306969T2 (de) | 1992-10-05 | 1997-05-07 | Hybridon Inc | Therapeutisches anti-hiv oligonukleotid und arzneimittel |
US5567604A (en) | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
HUT74597A (en) | 1993-06-23 | 1997-01-28 | Genesys Pharma Inc | Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection |
WO1995003407A2 (en) | 1993-07-19 | 1995-02-02 | Gen-Probe Incorporated | Oligonucleotides with activity against human immunodeficiency virus |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US20030050263A1 (en) | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US5932556A (en) | 1995-09-17 | 1999-08-03 | Tam; Robert C | Methods and compositions for regulation of CD28 expression |
GB9505438D0 (en) | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
US6030955A (en) | 1996-03-21 | 2000-02-29 | The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. | Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof |
ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
PL334197A1 (en) | 1996-12-27 | 2000-02-14 | Icn Pharmaceuticals | Oligonucleotidic aptamers of high g content and methods of modulating immunilogical response |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US20030064945A1 (en) | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
AU7589398A (en) | 1997-05-19 | 1998-12-11 | Merck & Co., Inc. | Oligonucleotide adjuvant |
CA2301575C (en) | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US20040006034A1 (en) | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1009440B1 (en) | 1997-07-03 | 2008-09-17 | MacFarlane, Donald E. | Method for inhibiting immunostimulatory dna associated responses |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
AU757175B2 (en) | 1997-09-05 | 2003-02-06 | Regents Of The University Of California, The | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
US20050031638A1 (en) | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
NZ507641A (en) | 1998-03-27 | 2003-09-26 | Immunex Corp | Nk cell activation inducing ligand (nail) dna and polypeptides and use thereof |
EP1067956B1 (en) | 1998-04-03 | 2007-03-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
AU3884199A (en) | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
DE69927495T2 (de) | 1998-05-14 | 2006-07-06 | Coley Pharmaceutical Group, Inc., Wellesley | Verfahren zur regulieren der hämatopoese mit hilfe von cpg-oligonukleotiden |
DE69932717T2 (de) | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | Methoden und produkte zur induzierung mukosaler immunität |
US6881561B1 (en) | 1998-05-27 | 2005-04-19 | Cheil Jedang Corporation | Endonuclease of immune cell, process for producing the same and immune adjuvant using the same |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
ES2226414T3 (es) | 1998-06-10 | 2005-03-16 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Estimulacion del sistema inmunitario. |
US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
EP1100807A1 (en) | 1998-07-27 | 2001-05-23 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
EP1108017A2 (en) | 1998-09-03 | 2001-06-20 | Coley Pharmaceutical GmbH | G-motif oligonucleotides and uses thereof |
US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
FR2783170B1 (fr) | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | Emulsion immunostimulante |
FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
WO2000061151A2 (en) | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
EP1177439B1 (en) | 1999-04-29 | 2004-09-08 | Coley Pharmaceutical GmbH | Screening for immunostimulatory dna functional modifiers |
AU4992900A (en) | 1999-05-06 | 2000-11-21 | Immune Response Corporation, The | Hiv immunogenic compositions and methods |
NZ515957A (en) | 1999-06-08 | 2003-08-29 | Aventis Pasteur | Immunostimulant oligonucleotide |
AU6051800A (en) | 1999-06-16 | 2001-01-02 | University Of Iowa Research Foundation, The | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
DE19935756A1 (de) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
ATE333284T1 (de) | 1999-09-27 | 2006-08-15 | Coley Pharm Group Inc | Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
AU2593701A (en) | 1999-12-21 | 2001-07-03 | Regents Of The University Of California, The | Method for preventing an anaphylactic reaction |
WO2001095935A1 (en) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
FR2805265B1 (fr) | 2000-02-18 | 2002-04-12 | Aventis Pasteur | Oligonucleotides immunostimulants |
US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
US20040131628A1 (en) | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
CA2410371C (en) | 2000-06-22 | 2015-11-17 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
US20020165178A1 (en) | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
US20020198165A1 (en) | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
US20020091097A1 (en) | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
WO2002022809A2 (en) | 2000-09-15 | 2002-03-21 | Coley Pharmaceutical Gmbh | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
FR2814958B1 (fr) | 2000-10-06 | 2003-03-07 | Aventis Pasteur | Composition vaccinale |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
ATE398175T1 (de) | 2000-12-08 | 2008-07-15 | Coley Pharmaceuticals Gmbh | Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung |
US20030055014A1 (en) | 2000-12-14 | 2003-03-20 | Bratzler Robert L. | Inhibition of angiogenesis by nucleic acids |
CA2430691A1 (en) | 2000-12-27 | 2002-07-04 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
US20030050268A1 (en) | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
PT1404873E (pt) | 2001-06-21 | 2013-07-30 | Dynavax Tech Corp | Compostos de imunomodulação quiméricos e métodos de utilização dos mesmos |
WO2003012061A2 (en) | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
AU2002326561B2 (en) | 2001-08-07 | 2008-04-03 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
WO2003015711A2 (en) | 2001-08-17 | 2003-02-27 | Coley Pharmaceutical Group, Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
CA2461315A1 (en) | 2001-10-05 | 2003-04-17 | Coley Pharmaceutical Gmbh | Toll-like receptor 3 signaling agonists and antagonists |
JP2005519990A (ja) | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物 |
US6838227B2 (en) * | 2001-11-30 | 2005-01-04 | Seagate Technology Llc | Polystyrene as a resist for making patterned media |
ES2543710T3 (es) | 2002-04-04 | 2015-08-21 | Zoetis Belgium S.A. | Oligorribonucleótidos inmunoestimulantes que contienen G y U |
WO2003103586A2 (en) | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
WO2004007743A2 (en) | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
WO2004026888A2 (en) | 2002-09-19 | 2004-04-01 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
CN1753687A (zh) | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
DE60329223D1 (de) | 2002-12-23 | 2009-10-22 | Dynavax Tech Corp | Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung |
US20040235770A1 (en) | 2003-04-02 | 2004-11-25 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
WO2004094671A2 (en) | 2003-04-22 | 2004-11-04 | Coley Pharmaceutical Gmbh | Methods and products for identification and assessment of tlr ligands |
KR20060016817A (ko) | 2003-06-20 | 2006-02-22 | 콜리 파마슈티칼 게엠베하 | 소분자 톨-유사 수용체 (tlr) 길항제 |
WO2005030259A2 (en) | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
KR100558851B1 (ko) | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 CpG 올리고데옥시뉴클레오티드변형체 |
JP2007526253A (ja) | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫刺激性ウイルスrnaオリゴヌクレオチド |
JP2007531746A (ja) | 2004-04-02 | 2007-11-08 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Il−10応答を誘導するための免疫活性化核酸 |
JP2008501807A (ja) | 2004-06-08 | 2008-01-24 | コーリー ファーマシューティカル ゲーエムベーハー | 抗原ならびに免疫活性化アゴニストおよび免疫活性化アンタゴニストのための担体基本骨格としての無塩基オリゴヌクレオチド |
CA2574090A1 (en) | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
EP1781325A2 (en) | 2004-07-18 | 2007-05-09 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
CA2598992A1 (en) | 2005-02-24 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
EP1874325A2 (en) | 2005-04-08 | 2008-01-09 | Coley Pharmaceutical Group, Inc. | Methods for treating infectious disease exacerbated asthma |
US20060241076A1 (en) | 2005-04-26 | 2006-10-26 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
EP1957647B1 (en) | 2005-11-25 | 2015-03-04 | Zoetis Belgium S.A. | Immunostimulatory oligoribonucleotides |
MX2008008279A (es) | 2005-12-20 | 2009-03-04 | Idera Pharmaceuticals Inc | Actividad inmunoestimuladora de oligonucleotidos inmunoestimuladores palindromicos que contienen diferentes longitudes de segmentos palindromicos. |
DK1991678T4 (da) | 2006-02-15 | 2020-10-19 | Rechtsanwalt Thomas Beck | Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer |
US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
AU2007300378A1 (en) | 2006-09-27 | 2008-04-03 | Coley Pharmaceutical Gmbh | Compositions of TLR ligands and antivirals |
EP2104738A2 (en) | 2006-10-26 | 2009-09-30 | Coley Pharmaceuticals GmbH | Oligoribonucleotides and uses thereof |
-
2002
- 2002-08-19 WO PCT/US2002/026468 patent/WO2003015711A2/en active Search and Examination
- 2002-08-19 ES ES02768621T patent/ES2314099T3/es not_active Expired - Lifetime
- 2002-08-19 BR BR0211962-5A patent/BR0211962A/pt not_active Application Discontinuation
- 2002-08-19 NZ NZ531194A patent/NZ531194A/en not_active IP Right Cessation
- 2002-08-19 SG SG2006010128A patent/SG177000A1/en unknown
- 2002-08-19 MX MXPA04001458A patent/MXPA04001458A/es active IP Right Grant
- 2002-08-19 JP JP2003520672A patent/JP4383534B2/ja not_active Expired - Fee Related
- 2002-08-19 CN CN028182138A patent/CN1604795B/zh not_active Expired - Fee Related
- 2002-08-19 KR KR1020047002289A patent/KR100991644B1/ko active IP Right Grant
- 2002-08-19 EA EA200400319A patent/EA007232B1/ru not_active IP Right Cessation
- 2002-08-19 DK DK02768621T patent/DK1446162T3/da active
- 2002-08-19 AU AU2002331643A patent/AU2002331643B2/en not_active Ceased
- 2002-08-19 SI SI200230776T patent/SI1446162T1/sl unknown
- 2002-08-19 DE DE60229422T patent/DE60229422D1/de not_active Expired - Lifetime
- 2002-08-19 PT PT02768621T patent/PT1446162E/pt unknown
- 2002-08-19 CA CA2457485A patent/CA2457485C/en not_active Expired - Lifetime
- 2002-08-19 IL IL16015702A patent/IL160157A0/xx unknown
- 2002-08-19 NZ NZ552377A patent/NZ552377A/en not_active IP Right Cessation
- 2002-08-19 EP EP02768621A patent/EP1446162B1/en not_active Expired - Lifetime
- 2002-08-19 US US10/224,523 patent/US8834900B2/en not_active Expired - Fee Related
- 2002-08-19 AT AT02768621T patent/ATE411054T1/de active
-
2004
- 2004-02-01 IL IL160157A patent/IL160157A/en unknown
- 2004-02-25 ZA ZA2004/01531A patent/ZA200401531B/en unknown
-
2005
- 2005-01-03 HK HK05100001.2A patent/HK1067547A1/xx not_active IP Right Cessation
-
2008
- 2008-10-03 JP JP2008259120A patent/JP2009028051A/ja not_active Withdrawn
- 2008-12-03 CY CY20081101400T patent/CY1109398T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001022972A2 (en) * | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
WO2001055370A2 (en) * | 2000-01-26 | 2001-08-02 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100991644B1 (ko) | 활성이 개량된 조합 모티프 면역자극성 올리고뉴클레오티드 | |
AU2002331643A1 (en) | Combination motif immune stimulatory oligonucleotides with improved activity | |
US9382545B2 (en) | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity | |
US8304396B2 (en) | Immunostimulatory nucleic acids | |
CN101160401A (zh) | 免疫刺激寡核苷酸 | |
JP2006512927A (ja) | 5’cpg核酸およびその使用方法 | |
TWI468166B (zh) | 具有增強之免疫刺激活性之經磷酸鹽修飾之寡核苷酸類似物 | |
KR20100045508A (ko) | 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 rna 서열 모티프 | |
AU2008200016B2 (en) | Combination motif immune stimulatory oligonucleotides with improved activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131011 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141010 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151008 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161014 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171017 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181012 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20191011 Year of fee payment: 10 |